Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736262 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
A Phase 2 study of Urticaria Chronic, sponsored by Jasper Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 19
- Study locations
NCT06736262 is a Phase 2 study of Urticaria Chronic that is active but no longer recruiting, run by Jasper Therapeutics. The registered enrollment target is 67 participants. The trial reports 19 study locations across 18 states.
The verdict
NCT06736262, a Phase 2 study of Urticaria Chronic, is active but no longer recruiting, sponsored by Jasper Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 19
- Study locations
Study Summary
Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
Conditions Studied
Interventions
- DRUG Briquilimab
Study Locations (19)
Maryland
- Investigative Site 101 - Baltimore
- Investigative Site 121 - White Marsh
Alabama
- Investigative Site 118 - Birmingham
Arkansas
- Investigative Site 108 - Little Rock
California
- Investigative Site 105 - San Diego
Florida
- Investigative Site 116 - Tampa
Idaho
- Investigative Site 109 - Boise
Illinois
- Investigative Site 124 - Normal
Indiana
- Investigative Site 110 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06736262
The ClinicalTrials.gov registry entry for NCT06736262 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jasper Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urticaria Chronic appearing as the primary indexed condition, and to 1 intervention - of which Briquilimab is the first listed.
NCT06736262 reports 19 study locations spanning 18 distinct geographic areas - top geographies include Maryland, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06736262 about?
NCT06736262 is a clinical study titled "A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials". Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
What is the current status of trial NCT06736262?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2024-11-26. Estimated completion is 2026-09-30.
What conditions does trial NCT06736262 study?
This clinical trial studies the following conditions: Urticaria Chronic.
What interventions are being tested in trial NCT06736262?
The interventions under investigation include: Briquilimab (DRUG).
Who is sponsoring clinical trial NCT06736262?
This trial is sponsored by Jasper Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736262 being conducted?
This trial has 19 study locations across Alabama, Arkansas, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urticaria Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.